Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2; no core content or functionality changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision: v3.4.1 was added, replacing Revision: v3.4.0, indicating a minor site version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedUI/metadata updates include adding a glossary display option, showing the label 'Last Update Submitted that Met QC Criteria', displaying 'No FEAR Act Data', and updating the revision to v3.4.0 (replacing v3.3.4) with minor capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no other study content or page functionality is affected.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter now displays Revision: v3.3.3; the HHS Vulnerability Disclosure line and the previous Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check91 days agoChange DetectedPublications section updated to clarify that publications are provided voluntarily by the person entering information and relate to the study results. Revision tag updated to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.